These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12716442)

  • 1. Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors.
    Mukherjee D; Topol EJ
    Arthritis Res Ther; 2003; 5(1):8-11. PubMed ID: 12716442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.
    Mukherjee D
    Biochem Pharmacol; 2002 Mar; 63(5):817-21. PubMed ID: 11911832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?
    Bing RJ; Lomnicka M
    J Am Coll Cardiol; 2002 Feb; 39(3):521-2. PubMed ID: 11823092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase inhibition and thrombogenicity.
    Catella-Lawson F; Crofford LJ
    Am J Med; 2001 Feb; 110 Suppl 3A():28S-32S. PubMed ID: 11173047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of cardiovascular events associated with selective COX-2 inhibitors.
    Mukherjee D; Nissen SE; Topol EJ
    JAMA; 2001 Aug 22-29; 286(8):954-9. PubMed ID: 11509060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2 inhibitor treatment of older osteoarthritis patients.
    Andersen SJ
    Compr Ther; 2003; 29(4):215-23. PubMed ID: 14989043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective COX-2 inhibitors: are they safe for the stomach?
    Yeomans ND; Cook GA; Giraud AS
    Gastroenterology; 1998 Jul; 115(1):227-9. PubMed ID: 9649482
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
    FitzGerald GA
    Am J Cardiol; 2002 Mar; 89(6A):26D-32D. PubMed ID: 11909558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selective inhibitors of cyclooxigenase-2 (Coxibs) and cardiovascular morbidity].
    Ruilope LM; Coca A
    Med Clin (Barc); 2002 Feb; 118(6):219-21. PubMed ID: 11864545
    [No Abstract]   [Full Text] [Related]  

  • 14. [Gastrointestinal and cardiovascular side effects associated with COX-2 selective inhibitors].
    Lanas A
    Med Clin (Barc); 2002 Feb; 118(6):237-8. PubMed ID: 11864548
    [No Abstract]   [Full Text] [Related]  

  • 15. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 16. COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.
    Hochberg MC
    Arthritis Res Ther; 2003; 5(1):28-31. PubMed ID: 12716445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.
    Wallace JL; Bak A; McKnight W; Asfaha S; Sharkey KA; MacNaughton WK
    Gastroenterology; 1998 Jul; 115(1):101-9. PubMed ID: 9649464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Benefits and risks of cyclooxygenase-2-selective inhibitor nonsteroidal antiinflammatory drugs].
    Vallano A; Llop R; Bosch M
    Med Clin (Barc); 2002 Oct; 119(11):429-34. PubMed ID: 12381279
    [No Abstract]   [Full Text] [Related]  

  • 19. COX-2: separating myth from reality.
    McKenna F
    Scand J Rheumatol Suppl; 1999; 109():19-29. PubMed ID: 10422543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-1 and COX-2 in health and disease.
    Adelizzi RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S7-12. PubMed ID: 10643175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.